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Introduction
The advent in 1996 of potent combination antiretroviral 
therapy (ART), sometimes called HAART (highly active 
antiretroviral therapy) or cART (effective combination 
antiretroviral therapy), changed the course of the HIV 
epidemic [1]. These “cocktails” of three or more antiretroviral 
drugs used in combination gave patients and scientists new 
hope for fighting the epidemic [2] and have significantly 
improved life expectancy—to decades rather than 
months [1,3].
For many years, scientists believed that treating HIV-infected 
persons also significantly reduced their risk of transmitting 
the infection to sexual and drug-using partners who did not 
have the virus. The circumstantial evidence was substantial, 
but no one had conducted a randomized clinical trial—
the gold standard for proving an intervention works. That 
changed in 2011 with the publication of findings from 
the HIV Prevention Trials Network (HPTN) 052 study, a 
randomized clinical trial designed in part to evaluate whether 
the early initiation of ART can prevent the sexual transmission 
of HIV among heterosexual couples in which one partner 
is HIV-infected and the other is not. This landmark study 
validated that early HIV treatment has a profound prevention 
benefit: results showed that the risk of transmitting HIV to an 
uninfected partner was reduced by 96% [4]. 
As a concept and a strategy, treating HIV-infected persons 
to improve their health and to reduce the risk of onward 
transmission—sometimes called treatment as prevention—
refers to the personal and public health benefits of using 
ART to continuously suppress HIV viral load in the blood and 
genital fluids, which decreases the risk of transmitting the 
virus to others. The practice has been used since the mid-
1990s to prevent mother-to-child, or perinatal, transmission 
of the virus. Research published in 1994 showed that 
zidovudine, more commonly known as AZT, when given 
to HIV-infected pregnant women and to their newborns 
reduced the risk of perinatal transmission from about 25% 
to 8% [5]. Since then, routinely testing pregnant women 
and treating infected mothers with ART during pregnancy, 
delivery, and while breastfeeding, when practiced according 
to recommendations, has reduced the mother’s risk of 
transmitting HIV to her child by 90% [6]. In one study, women 
who received at least 14 days of ART reduced the risk of 
transmitting HIV to their babies to less than 1% [7]. 
Putting Treatment as Prevention  
in Perspective
Treatment by itself is not going to solve the global HIV 
epidemic. On the domestic front, controlling and ultimately 
ending the epidemic will require a combination of 
scientifically proven HIV prevention tools as highlighted in 
the National HIV/AIDS Strategy (http://www.aids.gov/federal-
resources/national-hiv-aids-strategy/overview/), including 
 • Focusing on science-based HIV prevention efforts by 
supporting and expanding targeted use of high-impact 
HIV prevention approaches.
 • Making better investments by intensifying HIV 
prevention in the communities where HIV is most 
heavily concentrated.
 • Increasing access to HIV screening and medical care, 
including through
 o boosting federal investments for AIDS Drug  
Assistance Programs (ADAPs) to expand access to  
life-saving medications, and 
 o implementing the Affordable Care Act, which will 
increase health coverage for thousands of Americans 
living with HIV.
 • Sustaining a shared response to the domestic epidemic 
through the support of HIV prevention efforts across 
all levels of society, including federal, state, and local 
governments, faith-based communities, and the 
private sector.
Providing treatment to people living with HIV infection to 
improve their health must always be the first priority. Getting 
an HIV test is the first step to identifying persons with HIV 
infection and the pivotal entry point into the medical care 
system for both treatment and prevention. More than 1.1 
million persons in the United States are living with HIV, and 
almost 1 in 5 (18.1%) do not know they are infected [8]. By 
lowering the level of virus in the body, early ART helps people 
with HIV live longer, healthier lives and also lowers their 
chances of transmitting HIV to others. Although observational 
data had suggested that ART significantly reduces viral load 
and the risk of sexual transmission of HIV in heterosexual 
couples where one partner is infected and the other is not 
[9,10], it was the HPTN 052 study that definitively showed 
that early treatment of HIV-infected persons dramatically 
cuts the rate of new infections. Studies of communities with 
high concentrations of injection drug users (IDUs) and men 
who have sex with men (MSM) have shown that as ART use 
increased within the community, the community’s viral load 
declined, as did rates of new HIV diagnoses [11,12]. However, 
it is critical to remember that the prevention benefit of 
treatment is not 100%, and there has been at least one report 
of HIV transmission from a person with suppressed viral load 
to an uninfected sexual partner [13]. 
For persons living with or at risk for HIV infection, 
emphasizing these fundamental safeguards will continue  
to be crucial:
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 • Knowing their HIV status through routine testing.
 • Getting into care soon after HIV diagnosis and starting 
antiretroviral treatment.
 • Remaining in care and staying on HIV treatment.
 • Modifying behaviors that reduce the probability of 
getting or spreading HIV—such as using condoms 
properly and consistently, reducing numbers of partners, 
and avoiding sharing needles and syringes.
Test and Treat
The ability of antiretroviral drugs to prevent secondary 
transmission of HIV from an infected person to an uninfected 
sexual or drug-using partner has led to several proposed 
“test-and-treat” strategies. Test-and-treat programs are 
based on the premise that the rate of new HIV infections 
will be maximally reduced by using aggressive methods to 
test and diagnose all people living with HIV infection, treat 
them with ART regardless of CD4 cell count or viral load at 
diagnosis, and link them to care. In one study, mathematical 
modeling suggested that a universal test-and-treat-strategy 
in which all adults aged 15 years or older are tested annually 
could control the South African epidemic, reducing both 
HIV incidence and mortality to less than 1 case per 1,000 
people per year within 10 years of full implementation of 
the strategy—and reducing prevalence of HIV infection to 
less than 1% within 50 years [14]. Other investigators have 
not been as optimistic about the ultimate benefits of this 
strategy. Only 50% of persons in the United States with HIV 
remain in care [15,16], and about 18% do not know they 
are infected; these persons may contribute to the onward 
transmission of HIV. In addition to expanding testing and 
treating HIV infection earlier, overcoming the challenges of 
undiagnosed infection and poor engagement in care will 
result in better care of HIV-infected populations and reduced 
numbers of new HIV infections [17,18].
Challenges and the Future  
of HIV Prevention
The landmark HPTN 052 clinical trial was conducted 
almost solely among heterosexual couples who, as part 
of the study, received frequent counseling related to HIV, 
sexually transmitted diseases (STDs), and family planning. 
Results of a recent observational study of more than 38,000 
serodiscordant heterosexual couples across China showed 
that treating the HIV-infected partner reduced the risk of 
transmitting HIV to the uninfected partner by 26%—a much 
more modest effect than that found in the HPTN 052 study 
couples. Unlike the couples enrolled in HPTN 052, the couples 
in China were not part of an intensive study, and data were 
not available on sexual risk factors, adherence to antiretroviral 
treatment, or virological treatment outcome measures [19]. 
Additional data are needed to estimate the prevention 
benefit of treatment for other populations, such as MSM, 
IDUs, and persons with acute or primary HIV infection [20], 
and in other settings such as North America and during 
routine clinical care.
As HIV treatment has evolved from a complicated regimen 
of numerous pills taken several times a day with severe side 
effects to a now once-daily pill with few side effects, some 
persons living with HIV may have become complacent about 
maintaining safer sex and safer injection use practices. 
Since HIV treatment became widely available in developed 
countries, several studies have shown a resurgence of HIV 
infections and increases in STDs, in particular syphilis, and 
especially among MSM [21]. Some studies have cautioned 
that the prevention benefits of effective ART would be offset 
by risk compensation, meaning that increases in risky sexual 
and injection-drug-use behavior might be observed as 
effective ART is widely disseminated [22-24]. However, results 
of one meta-analysis demonstrated that HIV-positive persons 
receiving ART, compared with those not receiving ART, did 
not show increased sexual risk behavior, even when therapy 
resulted in an undetectable viral load [25]. Yet, persons with 
HIV who believe that using ART or having a suppressed viral 
load protects them against transmitting HIV may be more 
likely to engage in unprotected sex or other risky behaviors. 
These behaviors might be amenable to change through 
prevention messages and other effective approaches [25-
28]. Making sure that preventive behaviors are sustained in 
communities facing higher risk of HIV infection is crucial [29]. 
The future of HIV prevention will be shaped by operational 
and implementation research on the efficacy of combination 
prevention strategies, of which treatment may be one 
component [30-32]. Providing treatment to all HIV-infected 
persons will be an important step—a recommendation that 
is included in the current Guidelines for the Use of Antiretroviral 
Agents in HIV-1-Infected Adults and Adolescents [33]. The 
Department of Health and Human Services panel based its 
recommendations primarily on mounting evidence showing 
the harmful impact of ongoing HIV replication on AIDS and 
non-AIDS disease progression. In addition, the updated 
recommendations reflect emerging data showing the benefit 
of effective ART in preventing secondary transmission of HIV. 
Although the panel agrees that this public health benefit of 
ART is significant, its recommendations on when to begin 
ART are based primarily on the benefit of treatment to the 
HIV-infected individual [33]. If treatment is to achieve its full 
prevention potential, current gaps in the HIV prevention, 
treatment, and care continuum must be narrowed or closed. 
Considerable changes in the US health care delivery system 
will be required to accommodate the increased demand for 
services that expanded testing, treatment, and linkage and 
retention in care will bring [34]. 
Now that early ART of HIV-infected persons has been shown 
to be very effective at preventing secondary transmission of 
HIV among individuals, the current goal is to determine the 
extent to which ART can be used broadly and effectively to 
reduce the spread of HIV within a population. At least two 
community randomized trials that use ART as their basis are 
planned [35], and the results could determine the conclusive 
benefit of this successful intervention [36]. 
Still, resource constraints, logistical hurdles, emergence of 
drug-resistant viral strains, adherence to therapy regimens, 
Page 3 of 4
and risk compensation remain concerns that scientists, 
health care providers, policy makers, and communities 
must confront if the individual and public health benefits of 
treatment are to be fully realized [37].
What CDC Is Doing 
Much of CDC’s funding supports and expands prevention 
services for persons living with HIV, including 
 • Linkage to care and treatment, and interventions to 
improve retention in and re-engagement to care, 
prevention, and treatment for people living with HIV.
 • Referral to other medical and social services, such as 
substance abuse and mental health services.
 • Behavioral interventions and other risk-reduction 
services for HIV-positive persons and their sexual or 
needle-sharing partners to reduce the likelihood of  
HIV transmission. 
Three evidence-based interventions have proved effective in 
treatment settings and can be delivered by providers as brief 






CDC’s Prevention IS Care (http://www.cdc.gov/actagainstaids/) 
campaign also emphasizes ongoing, brief prevention 
counseling to help health care providers integrate into 
routine care simple approaches to prevent transmission 
by persons living with HIV. Medical visits provide a vital 
opportunity to reinforce HIV prevention messages, discuss 
sexual and drug-related risk behaviors, diagnose and treat 
other STDs, review the importance of medication  
adherence, and foster open communication between 
provider and patient.
Expanded HIV testing efforts will help more people know 
their status so that they can get life-saving treatment and 
will strengthen the impact of efforts to increase adherence 
to treatment, particularly in areas where large numbers of 
persons remain undiagnosed. 
Additionally, CDC and the Health Resources and Services 
Administration have supported studies that suggest several 
promising opportunities to improve retention in care, 
including collaborating with other service providers to 
identify persons poorly retained in care, enhancing outreach 
programs, and addressing unmet psychosocial needs [38,39]. 
Summary
To realize the full prevention benefit of treating HIV infection, 
we should keep in mind four overarching tenets:
 • HIV testing is the foundation for both prevention and 
care efforts.
 • Early identification of infection empowers individuals to 
take action that benefits both their own health and the 
public health.
 • Early treatment of infected persons substantially  
reduces their risk of transmitting HIV to others. 
 • The prevention benefit of treatment can only be  
realized with effective treatment, which requires  
linkage to and retention in care, and adherence to 
antiretroviral therapy.
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Get answers to questions and 
locate HIV testing sites.
CDC HIV Web Site 
www.cdc.gov/hiv
CDC National HIV Testing 
Resources 
http://hivtest.cdc.gov 
Text your ZIP code to KNOW IT 
or 566948. Locate an HIV testing 
site near you.
CDC National Prevention 
Information Network (NPIN) 
1-800-458-5231 
www.cdcnpin.org 





Treatment and clinical trials.
AIDS.gov 
www.aids.gov 
Comprehensive government 
HIV resources.
